Abbott Laboratories (ABT) Payables (2009 - 2026)

Abbott Laboratories has disclosed Payables across 18 years of filings, most recently posting $5.9 billion for Q2 2026.

• In Q2 2026, Payables rose 10.33% year-over-year to $5.9 billion; the TTM figure through Jun 2026 stood at $5.9 billion (up 10.33% YoY), while the FY2025 annual figure was $5.3 billion, up 2.26% from the prior year.
• Payables came in at $5.9 billion for Q2 2026 at Abbott Laboratories, up from $5.8 billion in the prior quarter.
• In the past five years, Payables ranged from a high of $5.9 billion in Q2 2026 to a low of $4.8 billion in Q3 2023.
• Average Payables over 5 years is $5.3 billion, with a median of $5.2 billion recorded in 2024.
• Year-over-year, Payables fell 9.42% in 2023 and gained 10.33% in 2026.
• Over 5 years, Payables stood at $5.5 billion in 2022, then slipped by 4.44% to $5.2 billion in 2023, then dropped by 0.59% to $5.2 billion in 2024, then advanced by 2.26% to $5.3 billion in 2025, then rose by 10.31% to $5.9 billion in 2026.
• Per Business Quant data, the three most recent Payables figures were $5.9 billion in Q2 2026, $5.8 billion in Q1 2026, and $5.3 billion in Q4 2025.